

## FACT SHEET

# Making Rare Disease Research Easier for Patients, Easier for Everyone.

Increase patients' access to novel treatments without burden



Clinical trials for rare diseases have always presented challenges. From investigator training to data collection, conducting clinical research for orphan disorders is mired with condition-specific challenges that slow development and place an enormous burden on patients wanting to participate in a potentially life-saving clinical trial.

By adding a Science 37 Metasite™ or virtual site, rare disease researchers can reduce participation burden on patients, their caregivers and on investigators – and bring clinical trials directly into patients' homes.

### Reduce Burden for Patients and Caregivers

By bringing research to patients, you can help to reduce burden and risk associated with travel to and from a physical site and for patients already suffering from a rare disease. This time saved and decreased risk is important not only to them but also for their caregivers. And without the limitations of geography, you can accelerate enrollment time and offer research options to patients who otherwise could not have participated.

### Find Patients and Investigators

Rare disease studies pose unique geographic challenges in recruiting patients and activating investigators to participate in a trial. With a decentralized model and targeted, data-driven recruitment approaches, such as disease registries to identify possible study participants, you can more easily find and identify rare disease patients. The Science 37 Metasite model can empower those patients' physicians to become telemedicine investigators – increasing physicians' access to novel treatment pathways for their patients and preserving the patient-physician relationship.

### Make It Easier for Everyone

With the Agile Clinical Trial Operating System™, Science 37 enables workflow orchestration, evidence generation and data harmonization on a unified, seamless technology platform, with standardized processes and connected to centralized networks – making it easy for patients with more agile design for faster development.

### The Endpoints That Matter

An agile and decentralized clinical trial approach for rare disorders is a patient-centric approach. From exploring various factors and considerations when selecting technology – such as patient engagement platforms, bring-your-own-device capabilities or wearable data collection devices – to ensuring patient-focused study design and patient-important endpoints, the ability to configure an effective rare disease study requires a centralized Operating System.

## CONFIGURABLE FOR RARE DISEASE

Science 37 offers configurable solutions. Our in-depth decentralized expertise, unparalleled experience and proven delivery enable support for any study, anywhere.



### Technology Configurations

*Purpose-built* technology platform to enable seamless agile trial execution with a unified, seamless platform for *workflow orchestration, evidence generation and data harmonization.*



### Network Configurations

Our networks are *integrated, agile and on-demand*, providing us the ability to orchestrate any study, including our patient communities, telemedicine investigators, provider communities, mobile nurses, remote coordinators, and data and devices.



### Study Configurations

From *early phase, pivotal studies, long-term follow-up and real-world evidence*, we can configure our OS to meet a study's needs with our expertise in virtualizing a number of indications.

Learn more.

[sales@science37.com](mailto:sales@science37.com) | [science37.com](https://science37.com)



#### About Science 37

Science 37 Holdings, Inc.'s (Nasdaq: SNCE) mission is to enable universal access to clinical research — making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 Agile Clinical Trial Operating System (OS) supports today's more agile clinical research designs with its full stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 15x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization.